Evidence map›Paper›PMID 37546995›Full record

ArticlebioRxiv : the preprint server for biology2023

Marco De Giorgi, So Hyun Park, Adam Castoreno, Mingming Cao, Ayrea Hurley, Lavanya Saxena, Marcel A Chuecos, Christopher J Walkey, Alexandria M Doerfler, Mia N Furgurson and 17 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Marco De GiorgiDepartment of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA.
So Hyun ParkDepartment of Bioengineering, Rice University, Houston, TX 77030, USA.
Adam CastorenoAlnylam Pharmaceuticals Inc, 675 W Kendall St, Cambridge, MA 02142, USA.
Mingming CaoDepartment of Bioengineering, Rice University, Houston, TX 77030, USA.
Ayrea HurleyDepartment of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA.
Lavanya SaxenaDepartment of Bioengineering, Rice University, Houston, TX 77030, USA.
Marcel A ChuecosDepartment of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA.
Christopher J WalkeyDepartment of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA.
Alexandria M DoerflerDepartment of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA.
Mia N FurgursonDepartment of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA.
M Cecilia LjungbergDepartment of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
Kalyani R PatelDepartment of Pathology, Texas Children's Hospital, Houston, TX 77030, USA.
Sarah HydeAlnylam Pharmaceuticals Inc, 675 W Kendall St, Cambridge, MA 02142, USA.
Tyler ChickeringAlnylam Pharmaceuticals Inc, 675 W Kendall St, Cambridge, MA 02142, USA.
Stephanie LefebvreAlnylam Pharmaceuticals Inc, 675 W Kendall St, Cambridge, MA 02142, USA.
Kelly WassarmanAlnylam Pharmaceuticals Inc, 675 W Kendall St, Cambridge, MA 02142, USA.
Patrick MillerAlnylam Pharmaceuticals Inc, 675 W Kendall St, Cambridge, MA 02142, USA.
June QinAlnylam Pharmaceuticals Inc, 675 W Kendall St, Cambridge, MA 02142, USA.
Mark K SchlegelAlnylam Pharmaceuticals Inc, 675 W Kendall St, Cambridge, MA 02142, USA.
Ivan ZlatevAlnylam Pharmaceuticals Inc, 675 W Kendall St, Cambridge, MA 02142, USA.
Rich Gang LiDepartment of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA.
Jong KimDepartment of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA.
James F MartinDepartment of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA.
Karl-Dimiter BissigDepartment of Pediatrics, Alice and Y. T. Chen Center for Genetics and Genomics, Division of Medical Genetics, Duke University, Durham, NC 27710, USA.
Vasant JadhavAlnylam Pharmaceuticals Inc, 675 W Kendall St, Cambridge, MA 02142, USA.
Gang BaoDepartment of Bioengineering, Rice University, Houston, TX 77030, USA.
William R LagorDepartment of Integrative Physiology, Baylor College of Medicine, Houston, TX 77030, USA.

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9M
Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Geoffrey A Preidis · 2001 to 2026
$28.3M
Genetic Repair of Familial HypercholesterolemiaR01HL132840 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI LAGOR, WILLIAM RAYMOND · 2017 to 2025
$5.4M
Physiological Dissection of the Mevalonate PathwayR01DK124477 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI William Raymond Lagor, NOAH Freeman SHROYER · 2020 to 2026
$3.5M
BCM-Rice resource for the analysis of somatic gene editing in miceU42OD026645 · OD · BAYLOR COLLEGE OF MEDICINE · PI DICKINSON, MARY E, HEANEY, JASON D. · 2018 to 2022
$3.5M
Resource SectionU42OD035581 · OD · BAYLOR COLLEGE OF MEDICINE · PI Denise Grant Lanza · 2023 to 2026
$3.2M
HBB gene-editing for treating sickle cell diseaseR01HL152314 · NHLBI · RICE UNIVERSITY · PI BAO, GANG · 2020 to 2023
$2.5M
Velcro AAV Vector for tissue-specific delivery of genome editing reagents with enhanced cargo capacityUG3HL151545 · NHLBI · RICE UNIVERSITY · PI BAO, GANG, LAGOR, WILLIAM RAYMOND · 2019 to 2021
$2.3M
Therapeutic pathway reprogramming for metabolic liver diseaseR01DK115461 · NIDDK · DUKE UNIVERSITY · PI BISSIG, KARL-DIMITER · 2018 to 2020
$1.1M
Therapeutic pathway reprogramming for metabolic liver diseaseR56DK115461 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI BISSIG, KARL-DIMITER · 2017 to 2017
$238k
NCI NIH HHS P30 CA125123NHLBI NIH HHS R01 HL132840NHLBI NIH HHS R01 HL152314NHLBI NIH HHS UG3 HL151545NIDDK NIH HHS P30 DK056338NIDDK NIH HHS R01 DK115461NIDDK NIH HHS R01 DK124477NIDDK NIH HHS R56 DK115461NIH HHS U42 OD026645NIH HHS U42 OD035581
6 · The paper itself

Abstract

Homology Directed Repair (HDR)-based genome editing is an approach that could permanently correct a broad range of genetic diseases. However, its utility is limited by inefficient and imprecise DNA repair mechanisms in terminally differentiated tissues. Here, we tested "Repair Drive", a novel method for improving targeted gene insertion in the liver by selectively expanding correctly repaired hepatocytes

Identifiers

PMID37546995
PMCPMC10402145

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.